Fluocinonide

Glucocorticoids possess extensive and potent pharmacol. effects, but their misuse and overuse are widespread concerns.Consequently, the environmental pollution and health hazards associated with their excessive usage cannot be overlooked.There is an urgent need for enhanced removal and a thorough understanding of the environmental and safety risks arising from the overconsumption of these drugs.In this study, a novel F, N-enriched covalent organic framework (designated as TAPT-COF) with high crystallinity was synthesized.TAPT-COF features numerous active sites, including F-F interaction and hydrogen bond interaction sites, along with a high sp. surface area and good thermal stability.These characteristics enable TAPT-COF to serve as an advanced adsorbent for dispersed solid-phase extraction (D-SPE) of glucocorticoids such as fluocinonide acetate, budesonide, and dexamethasone, with adsorption capacities ranging from 146.77 to 228.90 mg.g^-1 .Notably, TAPT-COF exhibits exceptional protein exclusion efficiency, achieving exclusion rates exceeding 95 %.Due to these advantages, TAPT-COF based D-SPE demonstrates strong applicability in the anal. of complex practical samples, including water and plasma, with satisfactory recoveries ranging from 76.48 % to 112.76 %.Compared to a COF (TPB-COF) that lacks a triazine group, TAPT-COF exhibits superior adsorption performance for target glucocorticoids.This is attributed to its ability to provide enhanced electrostatic interactions, as well as the synergistic effects of hydrogen bonding and F-F interactions.Addnl., TAPT-COF displays a low hemolytic activity, indicating its potential for in vivo anal.

Cemiplimab is a programmed cell death (PD-1) inhibitor used to treat metastatic and locally advanced cutaneous squamous cell carcinoma (SCC) and basal cell carcinoma (BCC).To the best of our knowledge, anti-PD-1-related mucositis and oral ulcerations have been reported in the literature, but in this article, we report a novel case of cemiplimab-induced gingival hyperplasia.A 65-yr-old male with a history of untreated hypertension and stage 3 chronic kidney disease presented with invasive, moderately differentiated SCC.The lesion initially presented on the right forehead and was resected via Mohs surgery in 2019.In early 2022, the patient developed right eye pain and visual disturbances, and imaging found a 2.0 9 1.6 cm right orbital mass.Subsequent biopsy by oculoplastics revealed a recurrence of his cutaneous SCC involving the orbit, and he was started on cemiplimab.Seven months after initiation of cemiplimab, the patient began experiencing gingival changes with significant erythema and hypertrophy of the upper and lower gingiva.Adverse drug reactions to immunotherapies complicate the management of any malignancy, and a robust understanding of these reactions is important for providers who are administering these medications.Although distinct from the typical dermatoses associated with checkpoint inhibitors, gingval hyperplasia falls under the umbrella of adverse mucocutaneous reactions, and our patient was continued on the cemiplimab given the significant improvement in his disease and otherwise excellent tolerability of the drug.